Search results for "pulmonary"

showing 10 items of 3030 documents

Outcome and attitudes toward home tracheostomy ventilation of consecutive patients: a 10-year experience.

2008

Summary Objectives To describe survival, predictors of long-term outcome and attitudes in patients treated at home by tracheostomy-intermittent positive-pressure ventilation (TIPPV) for respiratory failure during a 10-year period (1995–2004). Methods Seventy-seven consecutive patients were treated by TIPPV at home. Patients were divided into three groups: neuromuscular, pulmonary, and non-pulmonary patients. Effects of TIPPV on survival, factors influencing outcome after TIPPV, and attitudes of patients and caregivers regarding mechanical ventilation were studied. Results Forty-one patients (53%) were neuromuscular, 19 (25%) were affected by pulmonary diseases, and 17 (22%) by non-pulmonary…

Artificial ventilationPulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySurvivalHome Nursingmedicine.medical_treatmentRespiratory failureIntermittent Positive-Pressure VentilationPulmonary Disease Chronic ObstructiveTracheotomyTracheostomyInternal medicinemedicineCOPDHumansProspective StudiesProspective cohort studySurvival rateAgedMechanical ventilationAged 80 and overCOPDbusiness.industryTracheostomy mechanical ventilationRespiratory diseaseAmyotrophic Lateral SclerosisNeuromuscular DiseasesMiddle Agedmedicine.diseaseRespiration ArtificialSurgerySurvival RateCaregiversRespiratory failureFemaleALSbusinessRespiratory InsufficiencyAttitude to HealthRespiratory medicine
researchProduct

Effektivit�t pr�klinischer Notfallversorgung Fiktion oder Fakt?

1996

The current increase in the cost of health care must be considered as a severe threat to the prehospital emergency services system. Two examples have been selected--the patient with polytrauma and the patient in cardiac arrest--to demonstrate the dilemma between a need for objective data and the requirements of emergency patients. Study results obtained in trauma patients indicating that total prehospital time, including scene time, is correlated to patient outcome have led to the conclusion that at the scene treatment by emergency physicians may be dispensable. It has, however also been demonstrated that the time required for medical treatment at the scene is equivalent to 20% of the total…

Artificial ventilationmedicine.medical_specialtyEmergency managementbusiness.industryDefibrillationmedicine.medical_treatmentMEDLINEGeneral Medicinemedicine.diseasePolytraumaAnesthesiology and Pain MedicineVentricular fibrillationHealth caremedicineCardiopulmonary resuscitationIntensive care medicinebusinessDer Anaesthesist
researchProduct

Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acet…

2010

Pulmonary function is impaired in untreated mucopolysaccharidosis type VI (MPS VI). Pulmonary function was studied in patients during long-term enzyme replacement therapy (ERT) with recombinant human arylsulfatase B (rhASB; rhN-acetylgalactosamine 4-sulfatase). Pulmonary function tests prior to and for up to 240 weeks of weekly infusions of rhASB at 1 mg/kg were completed in 56 patients during Phase 1/2, Phase 2, Phase 3 and Phase 3 Extension trials of rhASB and the Survey Study. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1) and, in a subset of patients, maximum voluntary ventilation (MVV), were analyzed as absolute volume in liters. FEV1 and FVC showed little change f…

Arylsulfatase BAdultmedicine.medical_specialtyVital capacityAdolescentMucopolysaccharidoses (MPS)N-Acetylgalactosamine-4-SulfataseMucopolysaccharidosis type VIClinical SciencesUrologyPulmonary function testingPlacebos03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineRare DiseasesDouble-Blind MethodClinical ResearchmedicineGeneticsHumansGenetics(clinical)Longitudinal StudiesChildPreschoolLungGenetics (clinical)Genetics & Heredity0303 health sciencesLungMucopolysaccharidosis VIbusiness.industry030305 genetics & heredityEvaluation of treatments and therapeutic interventionsMucopolysaccharidosis VIEnzyme replacement therapyRecombinant Proteins3. Good healthSurgeryRespiratory Function Testsmedicine.anatomical_structureCross-Sectional StudiesResearch DesignChild Preschool6.1 PharmaceuticalsOriginal Articlebusiness030217 neurology & neurosurgery
researchProduct

Deep Vein Thrombosis

2015

Venous thromboembolism (VTE) comprises deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs at an incidence of 1/1,000 and risk factors include immobilization, hospitalization, surgery, thrombophilia and positive family history, cancer, pregnancy, and other hormonal effects. Commonly, clinical signs and symptoms for DVT are unreliable, especially in hospitalized patients, but the clinical assessment of the pretest probability, for example, with the Wells score, is an important component in the diagnostic algorithm, where compression ultrasound also plays a central role. Treatment of DVT aims to acutely prevent PE and short-term and long-term VTE recurrence and to avoid the lon…

Aspirinmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentStandard treatmentDeep veinCompression stockingsmedicine.diseaseThrombophiliaThrombosisPulmonary embolismSurgeryPre- and post-test probabilitymedicine.anatomical_structuremedicinecardiovascular diseasesbusinessmedicine.drug
researchProduct

Minimal clinically important difference for asthma endpoints: an expert consensus report

2020

Minimal clinically important difference (MCID) can be defined as the smallest change or difference in an outcome measure that is perceived as beneficial and would lead to a change in the patient's medical management.The aim of the current expert consensus report is to provide a “state-of-the-art” review of the currently available literature evidence about MCID for end-points to monitor asthma control, in order to facilitate optimal disease management and identify unmet needs in the field to guide future research.A series of MCID cut-offs are currently available in literature and validated among populations of asthmatic patients, with most of the evidence focusing on outcomes as patient repo…

Asthma asthma management minimal clinically important difference end-pointsPulmonary and Respiratory Medicinemedicine.medical_specialtyConsensusDelphi TechniqueEndpoint DeterminationBronchoconstrictionMEDLINEDelphi methodSocio-culturaleSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOminimal clinically important difference; asthma; lung function; biomarkersMCID03 medical and health sciences0302 clinical medicinePredictive Value of TestsmedicineHumansAnti-Asthmatic Agents030212 general & internal medicineDisease management (health)Intensive care medicineLungAsthmalcsh:RC705-779business.industryMinimal clinically important differenceminimal clinically important differenceExpert consensusend-pointslcsh:Diseases of the respiratory systemmedicine.diseaseMCID asthmaAsthmaTreatment Outcome030228 respiratory systemPredictive value of testsEndpoint DeterminationInflammation MediatorsSymptom AssessmentbusinessBiomarkersasthma managementEuropean Respiratory Review
researchProduct

Deconvolution procedure of the UV-vis spectra. A powerful tool for the estimation of the binding of a model drug to specific solubilisation loci of b…

2015

UV-vis-spectra evolution of Nile Red loaded into Tween 20 micelles with pH and [Tween 20] have been analysed in a non-conventional manner by exploiting the deconvolution method. The number of buried sub-bands has been found to depend on both pH and bio-surfactant concentration, whose positions have been associated to Nile Red confined in aqueous solution and in the three micellar solubilisation sites. For the first time, by using an extended classical two-pseudo-phases-model, the robust treatment of the spectrophotometric data allows the estimation of Nile Red binding constant to the available loci. Hosting capability towards Nile Red is exalted by the pH enhancement. Comparison between bin…

Atomic and Molecular Physics and OpticOxazineAnalytical chemistrySpecific solubilisation lociTween 20PolysorbatesDeconvolutionNile RedMicelleSpectral lineUV-vis spectraAnalytical ChemistrySurface-Active Agentchemistry.chemical_compoundSurface-Active AgentsUltraviolet visible spectroscopycmc; Deconvolution; Nile Red; Specific solubilisation loci; Tween 20; UV-vis spectra; Binding Sites; Oxazines; Polysorbates; Solubility; Spectrophotometry Ultraviolet; Surface-Active Agents; Micelles; Instrumentation; Atomic and Molecular Physics and Optics; Analytical Chemistry; Spectroscopy; Medicine (all)Pulmonary surfactantOxazinesInstrumentationSpectroscopyMicellesAqueous solutionBinding SitesChemistryMedicine (all)Nile redBinding SiteBinding constantAtomic and Molecular Physics and OpticsPolysorbateSolubilitycmcSpectrophotometry UltravioletDeconvolutionMicelle
researchProduct

Intraoperative Evaluation of the Reconstruction of the Atrioventricular Valves by Means of Transesophageal Echocardiography

1989

In 44 operations, the mitral valve was reconstructed in 28 patients, the tricuspid valve in 12, and both atrioventricular (AV) valves in four. The results of reconstruction were tested first in the open arrested heart by injection of a crystalloid solution into the left or right ventricle, either through the reconstructed valve or via one of the great arteries. Upon termination of cardiopulmonary bypass the valve function was examined in the beating heart by transesophageal contrast echocardiography (TEE). For purposes of visualization, 0.5–1.0 cc of agitated Gelifundol was injected into the ventricle. In 31 patients, open testing and echocardiographic visualization showed identical, good o…

Atrioventricular valvemedicine.medical_specialtyMitral valve repairTricuspid valvebusiness.industrymedicine.medical_treatmentlaw.inventionmedicine.anatomical_structureValve replacementVentriclelawGreat arteriesInternal medicineMitral valvemedicineCardiopulmonary bypassCardiologybusiness
researchProduct

Acetylcholine via Muscarinic Receptors Inhibits Histamine Release from Human Isolated Bronchi

1997

Human bronchi were incubated in organ baths to measure histamine release. The calcium ionophore A23187 (10 mumol/L; 1 min) stimulated histamine release by 148 +/- 28% (n = 11) above the prestimulation level but was ineffective in epithelium-denuded bronchi. Neither bradykinin (0.1 mumol/L) nor compound 48/80 (10 micrograms/ml) triggered the release of histamine from epithelium-intact bronchi. Acetylcholine did not affect spontaneous histamine release (about 2 nmol/g x 5 min) but inhibited A23187-evoked histamine release in an atropine-sensitive manner. Already a concentration as low as 0.1 nmol/L acetylcholine was effective, the maximal inhibition (by 89%) occurred at 100 nmol/L, whereas a …

AtropinePulmonary and Respiratory MedicineAgonistPhysostigminemedicine.medical_specialtyTime Factorsmedicine.drug_classPhysostigmineBradykininBronchiMuscarinic AntagonistsMuscarinic AgonistsCritical Care and Intensive Care MedicineHistamine Releasechemistry.chemical_compoundCulture TechniquesInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineHumansDrug InteractionsCalcimycinDose-Response Relationship DrugIonophoresbusiness.industryOxotremorineImmunoglobulin EReceptors MuscarinicAcetylcholineEndocrinologychemistryAcetylcholinesterase inhibitorDepression ChemicalCholinesterase InhibitorsbusinessAcetylcholineHistaminemedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Release of [3H]Acetylcholine in Human Isolated Bronchi: Effect of Indomethacin on Muscarinic Autoinhibition

1995

Receptor-mediated regulation of acetylcholine release in the airways, particularly in humans, remains unclear. In the present study, the tissue content of acetylcholine and release of [3H]acetylcholine were measured in freshly dissected human bronchi obtained at thoracotomy. Large (main and lobar bronchi) and small (segmental and subsegmental bronchi) airways contained considerable amounts of endogenous acetylcholine (300 +/- 50 pmol/100 mg wet weight), whereas significantly less was found in lung parenchyma (60 +/- 30 pmol/100 mg). Isolated small bronchi incubated in an organ bath with the precursor [3H]choline synthesized significant amounts of [3H]acetylcholine (26,000 +/- 4,000 dpm/100 …

AtropinePulmonary and Respiratory Medicinemedicine.medical_specialtyIndomethacinStimulationBronchiIn Vitro TechniquesCritical Care and Intensive Care Medicinechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineCholineHumansbusiness.industryOxotremorinerespiratory systemReceptors MuscarinicAcetylcholineElectric StimulationAtropineEndocrinologychemistryTetrodotoxinCholinergicbusinessAcetylcholinemedicine.drugAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoG…

2019

This multicenter/multinational, open-label, ascending-dose study (NCT01898364) evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of repeat-dose avalglucosidase alfa (neoGAA), a second-generation, recombinant acid α-glucosidase replacement therapy, in late-onset Pompe disease (LOPD). Patients ≥18 years, alglucosidase alfa naïve (Naïve) or previously receiving alglucosidase alfa for ≥9 months (Switch), with baseline FVC ≥50% predicted and independently ambulatory, received every-other-week avalglucosidase alfa 5, 10, or 20 mg/kg over 24 weeks. 9/10 Naïve and 12/14 Switch patients completed the study. Avalglucosidase alfa was well-tolerated; no deaths…

Avalglucosidase alfa (neoGAA)0301 basic medicineMaleGLUCOSE TETRASACCHARIDELysosomal acid alpha-glucosidase (GAA) deficiencyCHILDRENPulmonary function testingMOTOR FUNCTION0302 clinical medicineMedicineGenetics (clinical)Late-onset Pompe disease (LOPD)Glycogen Storage Disease Type IIAlglucosidase alfaMOUSE MODELEnzyme replacement therapyMiddle AgedTreatment OutcomeNeurologyTolerabilityEnzyme replacement therapySKELETAL-MUSCLEFemaleLife Sciences & BiomedicineMUSCLE TRAINING RMTGlycogen6-MINUTE WALKmedicine.drugAdultmedicine.medical_specialtyClinical NeurologyGLYCOGEN03 medical and health sciencesFEV1/FVC ratioPharmacokineticsInternal medicineHumansEnzyme Replacement TherapyAdverse effectAlglucosidase alfaScience & Technologybusiness.industryNeurosciencesalpha-GlucosidasesADULTSGlycogen storage disease type IISEVERITY030104 developmental biologyPharmacodynamicsPediatrics Perinatology and Child HealthNeurosciences & NeurologyNeurology (clinical)Glucan 14-alpha-Glucosidasebusiness030217 neurology & neurosurgeryNeuromuscular Disorders
researchProduct